{"id":"W4221104500","doi":"10.1158/1538-7445.sabcs21-pd15-01","title":"Abstract PD15-01: Impact of <i>ESR1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Cohort; Internal medicine; Fulvestrant; Oncology; Clinical endpoint; Hazard ratio; Progression-free survival; Clinical trial; Cancer; Estrogen receptor; Confidence interval; Breast cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001021841,0.0008660675,0.001263128,0.0008988419,0.0005031937,0.0001018401,0.0007248403,0.0001630496,0.002518128],"category_scores_gemma":[0.0001447122,0.0005547252,0.0003080466,0.002122492,0.0006627527,0.0005814531,0.000162784,0.002650549,0.00001004227],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004726169,"about_ca_system_score_gemma":0.001899495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005949234,"about_ca_topic_score_gemma":0.001235588,"domain_scores_codex":[0.9917757,0.001184458,0.001171665,0.001359094,0.003038868,0.001470236],"domain_scores_gemma":[0.9958424,0.001214259,0.0006327325,0.0008755479,0.001091381,0.0003436921],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8530101,0.007014218,0.02100305,0.0001009095,0.0007441139,0.0002419188,0.01368692,0.00387078,0.02895439,0.00002885132,0.0002550352,0.07108968],"study_design_scores_gemma":[0.1850458,0.02749073,0.7493083,0.001071822,0.00003248498,0.00001370982,0.002055903,0.00001434481,0.03373388,0.00009072225,0.000321061,0.0008212306],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809117,0.001275171,0.00000174934,0.002493233,0.0002160053,0.01029907,0.00463446,0.00006307619,0.0001055119],"genre_scores_gemma":[0.9844691,0.001589244,0.00008464648,0.0007225854,0.0004042867,0.01197755,0.0003627329,0.00023093,0.0001589294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7283053,"threshold_uncertainty_score":0.9996904,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03477374645994236,"score_gpt":0.380465132983951,"score_spread":0.3456913865240087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}